This chapter reviews how allosteric (heterotrophic) effectors and natural mutations impact
hemoglobin (Hb) primary physiological function of oxygen binding and transport. First, an …

For over 100 years, clinicians and scientists have been unravelling the consequences of the
A to T substitution in the β-globin gene that produces haemoglobin S, which leads to the …

The issue of treating sickle cell disease with drugs that increase hemoglobin oxygen affinity
has come to the fore with the US Food and Drug Administration approval in 2019 of …

Sickle cell anaemia (SCA) is the consequence of abnormal haemoglobin production due to
an inherited point mutation in the β‐globin gene. The resulting haemoglobin tetramer is …

The hallmark of sickle cell disease is the polymerization of sickle haemoglobin due to a point
mutation in the β‐globin gene (HBB). Under low oxygen saturation, sickle haemoglobin …

Polymerization of deoxy sickle cell hemoglobin (HbS) is well recognized as the primary
event that triggers the classic cycles of sickling/unsickling of patients red blood cells (RBCs) …

The oxygen demands of the human body require the constant circulation of blood carrying
an enormous concentration of hemoglobin (Hb). Oxygen transport depends not only on the …

Arylamines (AAs) and heterocyclic aromatic amines (HAAs) are structurally related
carcinogens formed during the combustion of tobacco or cooking of meat. They undergo …

This paper describes the synthesis and O2 binding properties of core–shell structured
hemoglobin (Hb) nanoparticles (NPs), artificial O2 carriers of five types, as designed for use …

Although it has been known for more than 60 years that the cause of sickle cell disease is
polymerization of a hemoglobin mutant, hydroxyurea is the only drug approved for treatment …